Current Report Filing (8-k)
May 13 2020 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 12, 2020
ClearPoint
Neuro, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
001-34822
|
58-2394628
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification Number)
|
5 Musick
Irvine, CA 92618
(Address of principal executive offices, zip code)
(949) 900-6833
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.01 par value per share
|
CLPT
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and
Financial Condition.
On May 12, 2020, ClearPoint
Neuro, Inc. (the “Company”) issued a press release announcing its financial performance for the first fiscal quarter
ended March 31, 2020 and providing an update with respect to its response to the COVID-19 pandemic. A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02
of this Current Report on Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01. Regulation
FD Disclosure.
The information set forth in Item 2.02 above is incorporated
by reference into this Item 7.01.
The information in Item 7.01 of
this Current Report on Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes
of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
Date: May 12, 2020
|
MRI INTERVENTIONS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Harold A. Hurwitz
|
|
|
|
Harold A. Hurwitz
|
|
|
|
Chief Financial Officer
|
MRI Interventions (AMEX:MRIC)
Historical Stock Chart
From Nov 2024 to Dec 2024
MRI Interventions (AMEX:MRIC)
Historical Stock Chart
From Dec 2023 to Dec 2024
